CN111132675B - 胆汁淤积性瘙痒的治疗 - Google Patents

胆汁淤积性瘙痒的治疗 Download PDF

Info

Publication number
CN111132675B
CN111132675B CN201880062348.XA CN201880062348A CN111132675B CN 111132675 B CN111132675 B CN 111132675B CN 201880062348 A CN201880062348 A CN 201880062348A CN 111132675 B CN111132675 B CN 111132675B
Authority
CN
China
Prior art keywords
pruritus
day
seladelpar
compound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880062348.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111132675A (zh
Inventor
波尔·布德斯
查尔斯·A·麦克沃特
亚历山德拉·S·斯坦伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Publication of CN111132675A publication Critical patent/CN111132675A/zh
Application granted granted Critical
Publication of CN111132675B publication Critical patent/CN111132675B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ladders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201880062348.XA 2017-09-26 2018-09-24 胆汁淤积性瘙痒的治疗 Active CN111132675B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26
US62/563,395 2017-09-26
PCT/US2018/052490 WO2019067373A1 (en) 2017-09-26 2018-09-24 TREATMENT OF CHOLESTATIC PRURIT

Publications (2)

Publication Number Publication Date
CN111132675A CN111132675A (zh) 2020-05-08
CN111132675B true CN111132675B (zh) 2023-04-25

Family

ID=64564950

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880062348.XA Active CN111132675B (zh) 2017-09-26 2018-09-24 胆汁淤积性瘙痒的治疗

Country Status (26)

Country Link
US (2) US20190105291A1 (https=)
EP (3) EP3973959B8 (https=)
JP (1) JP7023371B2 (https=)
KR (1) KR102376794B1 (https=)
CN (1) CN111132675B (https=)
AU (2) AU2018342323B2 (https=)
BR (1) BR112020005074A2 (https=)
CA (1) CA3076614C (https=)
CY (1) CY1124894T1 (https=)
DK (1) DK3973959T3 (https=)
ES (2) ES3012120T3 (https=)
FI (1) FI3973959T3 (https=)
HR (2) HRP20212010T1 (https=)
HU (2) HUE057377T2 (https=)
IL (2) IL273569B (https=)
LT (2) LT3687523T (https=)
MX (1) MX392537B (https=)
PL (2) PL3973959T3 (https=)
PT (2) PT3973959T (https=)
RS (1) RS62790B1 (https=)
SG (1) SG11202002253SA (https=)
SI (2) SI3687523T1 (https=)
SM (1) SMT202200171T1 (https=)
UA (1) UA125600C2 (https=)
WO (1) WO2019067373A1 (https=)
ZA (1) ZA202001646B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MX2022009776A (es) * 2020-02-10 2022-09-09 Genfit Tratamiento de la colangitis biliar primaria con elafibranor.
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies
JP2026509094A (ja) 2023-01-29 2026-03-17 シマベイ セラピューティクス, インコーポレーテッド 尿毒症性掻痒の治療
WO2024159051A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus
US20260060948A1 (en) 2024-07-31 2026-03-05 Cymabay Therapeutics, Inc. Methods for treating liver disease
CN121023009A (zh) * 2025-10-31 2025-11-28 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102734A (zh) * 2014-03-20 2016-11-09 西玛贝医药公司 肝内胆汁淤积性疾病的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102734A (zh) * 2014-03-20 2016-11-09 西玛贝医药公司 肝内胆汁淤积性疾病的治疗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A phase 2 proof of concept study of MBX-8025 in patients with Primary Biliary Cholangitis(PBC) who ar inadequate responders to ursodeoxycholic acid(UDCA);David Jones et al.;《HEPATOLOGY》;20161230;第1118-1140页 *

Also Published As

Publication number Publication date
EP3687523A1 (en) 2020-08-05
SI3687523T1 (sl) 2022-05-31
MX392537B (es) 2025-03-04
SMT202200171T1 (it) 2022-05-12
AU2021254641B2 (en) 2022-02-24
AU2018342323A1 (en) 2020-04-16
RS62790B1 (sr) 2022-02-28
CY1124894T1 (el) 2023-01-05
CN111132675A (zh) 2020-05-08
IL273569B (en) 2021-12-01
ES2902349T3 (es) 2022-03-28
EP3687523B1 (en) 2021-11-03
WO2019067373A1 (en) 2019-04-04
MX2020007273A (es) 2022-05-23
SG11202002253SA (en) 2020-04-29
IL288340B1 (en) 2023-01-01
EP3973959B1 (en) 2024-12-11
ES3012120T3 (en) 2025-04-08
PT3687523T (pt) 2021-12-06
KR20200058458A (ko) 2020-05-27
HUE070033T2 (hu) 2025-05-28
AU2021254641A1 (en) 2021-11-18
EP3973959B8 (en) 2025-01-15
PL3687523T3 (pl) 2022-02-21
UA125600C2 (uk) 2022-04-27
PL3973959T3 (pl) 2025-03-24
JP7023371B2 (ja) 2022-02-21
US20190105291A1 (en) 2019-04-11
BR112020005074A2 (pt) 2020-09-15
RU2020114644A (ru) 2021-10-27
LT3687523T (lt) 2022-03-25
NZ762976A (en) 2021-11-26
LT3973959T (lt) 2025-01-10
PT3973959T (pt) 2025-01-24
SI3973959T1 (sl) 2025-03-31
IL288340B2 (en) 2023-05-01
EP4523744A3 (en) 2025-06-04
US20210283078A1 (en) 2021-09-16
IL288340A (en) 2022-01-01
IL273569A (en) 2020-05-31
DK3973959T3 (da) 2025-01-20
ZA202001646B (en) 2021-08-25
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
CA3076614A1 (en) 2019-04-04
CA3076614C (en) 2023-02-07
HRP20212010T1 (hr) 2022-04-01
AU2018342323B2 (en) 2021-09-23
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (https=) 2022-02-14
EP3973959A1 (en) 2022-03-30
JP2020535225A (ja) 2020-12-03
HUE057377T2 (hu) 2022-05-28
FI3973959T3 (fi) 2025-02-03

Similar Documents

Publication Publication Date Title
CN111132675B (zh) 胆汁淤积性瘙痒的治疗
JP7079735B2 (ja) 肝内胆汁うっ滞性疾患の処置
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
AU2015231232A1 (en) Treatment of intrahepatic cholestatic diseases
HK40121699A (en) Treatment of cholestatic pruritus
HK40062783B (en) Treatment of cholestatic pruritus with seladelpar
HK40062783A (en) Treatment of cholestatic pruritus with seladelpar
RU2781281C2 (ru) Лечение холестатического зуда
HK40033446A (en) Treatment of cholestatic pruritus with seladelpar
HK40033446B (en) Treatment of cholestatic pruritus with seladelpar
NZ762976B2 (en) Treatment of cholestatic pruritus
JP7596548B2 (ja) 胆管症の治療

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant